Intratio
Loading...
Skip to main content
Model output · Signal date 2026-10-16

Nexalin Technology, Inc. (NXL) Stock Forecast Oct. 16, 2026

Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq

Follow Unlock full AI forecasts
Rating · 90D ▼ Bearish Exact rating locked
90-day forecast Sign up free to reveal
30-day forecast Alpha
Rank in coverage Bottom 35% of 5184 stocks scored
Rank correlation · 90D -8.0% Spearman, 342 dates
Market Cap $2M small-cap · #29 of 30 peers
Summary

Nexalin Technology, Inc. (NXL) stock forecast summary

Our AI ranks Nexalin Technology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

Nexalin Technology, Inc. is a small-cap company with a market capitalization of $2M. It ranks number 29 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast.

For NXL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -8.0%, measured on 342 forecast dates between 2022-11-11 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 385 forecast dates between 2022-11-11 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)

A free account shows the exact forecast, rating and rank of 3 tickers you follow, NXL included.

Follow NXL free
Price

NXL price chart and AI forecast

NXL
Cross-section · 2026-10-16

How NXL ranks among 5184 stocks

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Fundamentals · 2026-06-30

Nexalin Technology, Inc. (NXL) fundamentals

Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.

Valuation & Market

MetricNXLIndustry medianRank
Market Cap $2M $86M 29/30
P/B Ratio 1.28x 3.93x 20/23
EPS $-0.46 – –
Book Value/Share $1.83 – –

Profitability & Margins

MetricNXLIndustry medianRank
Gross Margin 81.6% 56.4% 5/27
Operating Margin -3734.9% -9.7% 28/28
EBT Margin -3673.4% -11.4% 28/28

Financial Health

MetricNXLIndustry medianRank
Current Ratio 1.25x 2.17x 24/30
Quick Ratio 1.10x 1.65x 20/29
D/E Ratio 0.98x 0.82x 11/25
Financial Leverage 1.98x 1.82x 11/25
Interest Coverage 1944.8x -12.8x 2/30
Working Capital $380K $20M 24/29

Cash Flow

MetricNXLIndustry medianRank
Operating Cash Flow -$7M -$2M 21/30

Operational Efficiency

MetricNXLIndustry medianRank
Inventory Turnover 0.2x 2.0x 26/27
Days Inventory 1668 days 184 days 2/27
Payables Period 1711 days 77 days 3/24

Income Statement

MetricNXLIndustry medianRank
Operating Income -$11M -$4M 21/30
R&D Expense $2M $9M 20/28
SG&A Expense $5M $43M 23/26
Cost of Goods Sold $50K $16M 26/27

Dividend & Shareholder Information

MetricNXLIndustry medianRank
Shares Outstanding 1M – –

Balance Sheet Highlights (USD millions)

Total Current Assets$2M61.9% of assets
Cash & Short-term Investments$1M33.3% of assets
Accounts Receivable$50K1.7% of assets
Inventory$230K7.7% of assets
Total Liabilities$1M49.3% of assets
Short-term Debt$1M41.6% of assets
Quarterly Financial Reports

NXL quarterly financials and insider trading

Industry Peers · Electromedical & Electrotherapeutic Apparatus

Nexalin Technology, Inc. (NXL) industry peers

Companies classified under the same SEC industry code as Nexalin Technology, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.

Reveal all forecasts · See exact % predictions for all competitors

Sign up free
Company 90-Day AI Forecast (Alpha) Market Cap P/E Ratio P/B Ratio
NXL Nexalin Technology, Inc. ▼ $2M – 1.3x
MDT Medtronic Plc ▼ $121.20B 23.3x 2.4x
ITGR Integer Holdings Corp ▼ $4.31B 49.9x 2.5x
LIVN Livanova Plc ▼ $4.27B 26.0x 3.2x
TMDX Transmedics Group, Inc. ▲ $2.45B 16.2x 4.7x
BLFS Biolife Solutions Inc ▶ $1.89B 32.6x 4.5x
AXGN Axogen, Inc. ▲ $1.86B – 7.3x
CNMD Conmed Corp ▼ $1.40B 22.4x 1.3x
CBLL Ceribell, Inc. ▲ $961M – 7.5x
INMD Inmode Ltd. ▼ $814M 7.2x 1.2x
CV Capsovision, Inc ▶ $327M 7.8x 24.8x
ELMD Electromed, Inc. ▼ $229M 21.1x 4.3x
FOCL Edap Tms Sa ▲ $153M – –
STXS Stereotaxis, Inc. ▶ $101M – –
VANI Vivani Medical, Inc. ▶ $101M – 5.3x
NRXS Neuraxis, Inc ▲ $97M – 14.4x
HYPR Hyperfine, Inc. ▲ $75M – 2.0x
OM Outset Medical, Inc. ▲ $74M – 0.8x
ECOR Electrocore, Inc. ▲ $71M – –
VASO Vaso Corp ▲ $51M – 1.8x
POSC Positron Corp ▲ $51M – –
QTI Qt Imaging Holdings, Inc. ▶ $35M – 15.6x
POCI Precision Optics Corporation, Inc. ▲ $34M – 1.7x
ITOC Itonic Holdings Ltd ▼ $28M – 4.6x
GTHP Guided Therapeutics Inc ▲ $18M – –
IRIX Iridex Corp ▲ $14M – 3.9x
NDRA Endra Life Sciences Inc. ▶ $7M – –
ADMT Adm Tronics Unlimited, Inc. ▶ $3M – 5.6x
NUWE Nuwellis, Inc. ▼ $2M – –
ESMC Escalon Medical Corp ▲ $1M 1.3x 0.3x
HCIL Hongchang International Co., Ltd ▼ N/A – –
YBGJ Yubo International Biotech Ltd ▶ N/A – –

Where NXL sits on the market map

Industrial Applications and Services · Electromedical & Electrotherapeutic Apparatus
Explore the map →
News

Nexalin Technology, Inc. (NXL) stock news

source: Benzinga on MSN

<?xml encoding="utf-8" ?> Nexalin Technology Inc. NXL stock surged Thursday after the micro-cap medical technology company signed a 10-year distribution and manufacturing agreement covering seven ...

More news available

Sign up free to read all 12 news articles and stay updated on market developments.

Sign Up Free to Read More
FAQ

Nexalin Technology, Inc. (NXL) stock forecast FAQ

What is the Nexalin Technology, Inc. (NXL) stock forecast?

Our AI ranks Nexalin Technology, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.

How accurate are Nexalin Technology, Inc. stock predictions?

For NXL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -8.0%, measured on 342 forecast dates between 2022-11-11 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 385 forecast dates between 2022-11-11 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report

How often are Nexalin Technology, Inc. forecasts updated?

Nexalin Technology, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.

Which companies are Nexalin Technology, Inc.'s industry peers?

32 issuers in our coverage, NXL included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.